USA flag logo/image

An Official Website of the United States Government

Neuroprotection in Stroke Drug Development

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
66692
Program Year/Program:
2003 / SBIR
Agency Tracking Number:
NS044654
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
ARMAGEN TECHNOLOGIES, INC.
26679 Agoura Rd. #100 Calabasas, CA -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2003
Title: Neuroprotection in Stroke Drug Development
Agency: HHS
Contract: 1R43NS044654-01A1
Award Amount: $100,000.00
 

Abstract:

DESCRIPTION (provided by applicant): There presently is no neuroprotective agent that can be given to patients with acute stroke. The costs for rehabilitation of patients that survive a stroke are greater than $40 billion per year in the U.S. The reason that an effective neuroprotective drug has not been developed so far, despite intensive efforts in the pharmaceutical industry, is that m most of the drugs do not cross the blood-brain barrier (BBB). Neurotrophins are potential large molecule neuroprotectives but these, too, do not cross the BBB. The present research plan aims at a merger of neurotrophin drug discovery and BBB drug targeting technology, so that a recombinant neurotrophin can be re-formulated to enable transport through the BBB in vivo. Such a drug will cause neuroprotection in stroke patients following intravenous administration. The goal of this work is to produce a genetically engineered fusion gene that encodes a fusion protein wherein the neurotrophin neuroprotective agent is fused to a genetically engineered chimeric monoclonal antibody (MAb) that undergoes receptor-mediated transport across the BBB in humans in vivo. The fusion protein will be a bi-functional molecule that not only crosses the BBB, but also binds to the target neurotrophin receptor in the brain in vivo. In phase I, the fusion gene will be produced and transiently. Transfected cell lines will be used to demonstrate the bi-functionality of the novel fusion protein. The bifunctionality of the fusion protein will be confirmed by immunoassay directed at both the BBB transporting receptor and the neurotrophin receptor. The phase 1_ work will produce a permanently transfected cell line secreting the fusion protein, and this protein will be manufactured and validated. At the completion of the phase II work, the company will be able to submit an IND to the FDA for testing of the new neuroprotective drug for stroke.

Principal Investigator:

Ruben J. Boado
3104590163
RBOADO@armagentech.com

Business Contact:

Ruben Boado
3109171275
RBOADO@MEDNET.UCLA.EDU
Small Business Information at Submission:

ARMAGEN TECHNOLOGIES, INC.
ARMAGEN TECHNOLOGIES, INC. 914 COLORADO BLVD SANTA MONICA, CA 90401

EIN/Tax ID: 954874550
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No